Summary
This Form 8-K filing by Merck & Co., Inc. (MRK) on March 11, 2010, details an amendment to a material definitive agreement concerning the potential contribution of Merck's animal health business, Intervet, to Merial Limited. This move is part of a broader agreement with sanofi-aventis, where sanofi-aventis holds a call option to acquire this business in exchange for a 50% equity stake in the combined entity. The amendment clarifies the conditions and timeline for executing a Contribution Agreement, particularly addressing the involvement and potential proceedings of a Works Council. Investors should note that on March 9, 2010, Merck and sanofi-aventis jointly announced that sanofi-aventis had exercised its call option. This 8-K filing provides further procedural details and agreements surrounding the exercise and the path towards finalizing the transaction. The core of the transaction involves the combination of Merck's Intervet animal health operations with Merial, a joint venture, with sanofi-aventis potentially becoming a co-owner of this combined business.
Key Highlights
- 1Merck & Co., Inc. (Merck) and sanofi-aventis have amended their Call Option Agreement related to Merck's Intervet Animal Health Business.
- 2Sanofi-aventis has exercised its call option to acquire Merck's animal health business.
- 3The business will be contributed to Merial Limited in exchange for a 50% equity interest in the combined entity.
- 4The amendment specifies conditions and timelines for executing the Contribution Agreement, including considerations for the Works Council.
- 5Merck and sanofi-aventis will collaborate to mitigate adverse effects from any legal proceedings initiated by the Works Council.
- 6The amendment grants both parties additional termination rights for the Call Option Agreement under certain circumstances.
- 7A joint press release on March 9, 2010, confirmed sanofi-aventis' exercise of its option.